- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01862562
Trial to Evaluate Laparoscopic Versus Open Surgery in Elderly Colorectal Cancer Patients
Randomized Controlled Trial to Evaluate Laparoscopic Versus Open Surgery in Elderly Colorectal Cancer Patients Who Were 75 Years Old or Over
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients
- This was a randomized controlled trial conducted at a single institute, which was Yokohama City University Medical Center (Japan).
- 200 patients were age of 75 years old or over were randomly allocated to receive laparoscopic surgery or conventional open surgery.
Surgical procedures
- All surgical procedures were performed by one specialized colorectal treatment team. The laparoscopic surgeries were performed by a surgeon who passed the skill accreditation system for laparoscopic gastroenterological surgery was established by the Japanese Society for Endoscopic Surgery (JSES), and all open surgeries were performed under the supervision of these skillful surgeons.
- All operations were performed according to the standard radical cure procedure described in the seventh edition of the Japanese General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. That is, intestinal excision with lymph node dissection that separated the feeding blood vessel at its origin was performed in all surgical procedures. Patients who underwent palliative partial excision were not included.
- In the laparoscopic surgery, a medial-to-lateral approach was performed in all patients.
- In the conventional open surgery, the first procedure was done in lateral approach. The reconstruction techniques were the same as those used in laparoscopic surgery.
Randomization
- To balance the operative backgrounds between the laparoscopic and the conventional open surgery groups, the patients were stratified by the tumor location (right colon, left colon and rectum).
- A transverse colon cancer was allocated to the right colon group, and a rectosigmoid cancer was allocated to the rectum group.
Adjuvant therapy
- When the pathological stage was diagnosed as stage 3 by histological examination of the resected specimen, adjuvant chemotherapy was done with oral fluoropyrimidine anti-cancer drug.
- Neither radiation therapy nor preoperative chemotherapy was given to any patient. Preoperative chemo-radiotherapy even for rectal cancer is not yet standard treatment in Japan.
Assessment parameters
- The preoperative parameters
- Operative assessment parameters
- Postoperative assessment parameters An early postoperative complication was defined as a complication that occurred between the finish of the operation and postoperative day 30. A late postoperative complication was defined as a complication that occurred after postoperative day 30. The terminologies of complications were classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, and grading was done by Classification of Surgical Complication.
- The pathological results were recorded according to the 7th edition of the Japanese General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus and 7th edition of primary tumor, regional nodes, metastasis (TNM) classification. Circumferential margin involvement was defined as exposure of a cancer cell at the vertical dissection surface on histological examination.
- Quality of life (QOL) scores. The QOL score was measured using the 36-item Short Form Health Survey (SF-36) version 2.0. It is a tool that measures health-related QOL (HRQOL) according to an inclusive standard and not a disease-specific standard. The SF-36 is composed of 36 questions. The score is expressed numerically by the provided scoring algorithm. SF-36 questionnaires were sent to the patients at one month, 6 months and one year after the surgery by postal mail. A return envelope was enclosed with the SF-36 questionnaire, and the patient sent it back to the research secretariat by postal mail. A questionnaire on the defecation situation and wound pain besides the SF-36 was added all three times. The question of when complete rehabilitation occurred was added in the questionnaire at one year.
Follow-up schedule
- The follow-up schedule was as follows according to stage. Patients with stages 0 and 1 were followed up with outpatient examinations including tumor marker measurements, and chest, abdominal and pelvic computed tomography (CT) once a year for five years. Patients with stage 2 and 3a were examined by CT and tumor marker measurements every six months for the first two years. These examinations were done once a year from the third year to the fifth year. Patients with stage 3b and 3c were examined by CT and tumor marker measurements every four months for the first two years, and every six months from the third year to the fifth year.
Statistical analysis
- The primary endpoint was early complication rate.
- The secondary endpoints were 5-year overall survival, 3-year recurrence-free survival, length of postoperative hospital stay, and HRQOL score.
- A sample size of 200 patients was assured to achieve a power of more than 80% to detect a difference between the groups using a two-sided Chi-squared test with type I error rate equal to 0.05, when the true complication rates were 20% and 40% for the laparoscopic and open surgeries, respectively.
- For continuous variables, data are presented as means ± standard deviation (SD). For categorical variables, data are presented as frequencies and percentages (%). Comparison of the endpoints was based on intention-to-treat principle, that is, the patients who switched to another group during surgery were treated as members of the allocated group. The Chi-squared test was applied to evaluate the significance of differences in proportions, and t-test was used to evaluate the significance of differences in continuous variables. A p-value of less than 0.05 was considered to be statistically significant.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Kanagawa-ken
-
Yokohama, Kanagawa-ken, Japan, 232-0024
- Yokohama City University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age of 75 years old or over
- Histologically proven adenocarcinoma
- Clinical tumor penetrates visceral peritoneum (T4a), no metastasis (M0) or lower T factor
- Elective operation
- Tolerable surgery under general anesthesia
- No bulky tumor larger than 8cm in diameter
- No history of laparotomy for colorectal resection except appendectomy
- Provided written informed consent
Exclusion Criteria:
- Synchronous or metachronous (within 5 years) malignancy in another organ except carcinoma in situ
- Multiple colorectal cancer that needs reconstruction two or more times
- Acute intestinal obstruction or perforation due to colorectal cancer
- Lower rectal cancer that required pelvic side wall lymphadenectomy
- Pregnant or lactating women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Open surgery
Conventional procedure
|
Conventional technique
Other Names:
|
|
Experimental: Laparoscopic surgery
Minimum invasive procedure
|
New minimum invasive technique
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Early complication rate
Time Frame: 30 days after surgery
|
All complication due to surgical procedure within 30 days after surgery
|
30 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: 5 years
|
All death is defined as an event of overall survival.
The overall survival rate is appropriate to evaluate whether laparoscopic surgery influences survival which is the true target of malignant disease treatment for curable colorectal cancer by surgery.
|
5 years
|
|
Recurrence-free survival
Time Frame: 3 years
|
All death and recurrence from colorectal cancer are defined as an event of recurrence-free survival.
|
3 years
|
|
Length of postoperative hospital stay
Time Frame: 9 days
|
Length of postoperative hospital stay is defined as a duration between surgery and first discharge.
An expected average is 9days.
|
9 days
|
|
Health-related QOL score
Time Frame: 1 year after surgery
|
Short-Form 36 (SF36) is used for measurement of Health-related QOL score.
SF-36 questionnaires were sent to the patients at one month, 6 months and one year after the surgery by postal mail.
A return envelope was enclosed with the SF-36 questionnaire, and the patient sent it back to the research secretariat by postal mail.
A questionnaire on the defecation situation and wound pain besides the SF-36 was added all three times.
The question of when complete rehabilitation occurred was added in the questionnaire at one year.
|
1 year after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Chikara Kunisaki, Professor, Yokohama City University, Gastroenterological Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YCUMC-D1108015
- YokohamaCUMC34 (Other Identifier: YokohamaCUMC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Thomas...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...CompletedColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on Open surgery
-
Cai KailinUnknownLocally Advanced Gastric CancerChina
-
International Study Group on Minimally Invasive...Fondazione CARIT; LOGIX S.r.l.Unknown
-
Peking Union Medical College HospitalCompletedPancreatic Neuroendocrine TumorsChina
-
Peking University People's HospitalNot yet recruitingEndometrial Carcinoma | Tumor Molecular Features Screening Model
-
Ruijin HospitalShanghai Jiao Tong University School of MedicineRecruitingPancreatic Ductal Adenocarcinoma | Minimally Invasive SurgeryChina
-
University of CatanzaroUnknownSurgery | Outcome, Fatal | Abdominal Aortic AneurysmItaly
-
Beijing Friendship HospitalUnknown
-
Giresun UniversityCompletedPostoperative Pain | Minimally Invasive Surgical Procedure | Patient Discharge | Lateral Malleolus FractureTurkey
-
Sunnybrook Health Sciences CentreMcMaster University; Unity Health Toronto; University of Toronto; University of... and other collaboratorsCompleted
-
Hospital Central de la Defensa Gómez UllaClinica Universidad de Navarra, Universidad de NavarraEnrolling by invitationRectal Cancer | PROM | Functional Bowel DisorderSpain